We demonstrate that fusion proteins consisting of the her-COS cells transfected with tk alone. Tumours established pes simplex virus (HSV) transport protein VP22 linked in in mice with neuroblastoma cell lines expressing VP22-tk frame to HSV thymidine kinase (tk) retain the ability to be regressed upon administration of ganciclovir. Furthermore transported between cells. In vivo radiolabelling experitumours established from 50:50 mixtures of VP22-tk transments and in vitro assays show that the fusion proteins duced and nontransduced cells also regressed while no also retain tk activity. When transfected COS cells, acting significant effect was observed in similar experiments with as a source of the VP22-tk chimera, were co-plated on to cells transduced with tk alone. VP22 mediated transport gap junction-negative neuroblastoma cells, ganciclovir may thus have application in a clinical setting to amplify treatment induced efficient cell death in the recipient neurodelivery of the target protein in enzyme-prodrug protocols. blastoma cell monolayer. No such effect was observed with
Introduction
Within the developing field of gene therapy, one of the approaches most frequently explored in the treatment of cancer is that of enzyme-prodrug or suicide gene therapy. Approximately 10% of patients presently undergoing clinical trials are enlisted in such protocols. 1 The enzyme most commonly employed, both in an experimental and a clinical setting, is the herpes simplex virus thymidine kinase. This enzyme selectively converts nucleoside analogues, such as ganciclovir (GCV) into monophosphorylated forms, which are subsequently modified to toxic triphosphates by endogenous cellular enzymes and incorporated into nascent DNA causing chain termination and cell death. More than a dozen clinical trials using HSVtk are underway. 1, 2 Among the inherent problems in the general field of gene therapy, but particularly relevant in approaches to gene therapy of cancer is the issue of efficiency of delivery. 3 In suicide gene therapy a 'bystander effect' frequently occurs wherein cytotoxicity is observed in cells not transduced with the effector gene. This effect can help counteract poor or inefficient delivery of the therapeutic gene. 4, 5 Although several theories have emerged to explain the mechanism of the bystander effect including transfer of apoptotic vesicles, transduction of endothelial cells in tumour vessels, or induction of an antitumour immune response, we and others have demonstrated that gap junctions are important in mediating the bystander effect in vitro and in vivo. 4, 6, 7 However, a significant fraction of malignant tumours, 8 including the high-grade glioblastomas, 9 one of the main targets for therapy with HSVtk, poorly express connexin, a major gap junction protein, and thus exhibit little or no gap junction activity. Clearly promotion of a bystander effect by a route independent of, or in addition to, metabolite transport through gap junctions would be of significant benefit.
In this regard, the HSV-1 tegument protein VP22 exhibits the unusual property of intercellular spread whereby the protein is exported from the cytoplasm of expressing cells and subsequently imported into neighbouring cells where it accumulates in the nucleus. 10 Thus VP22 may offer significant enhancement or amplification in gene therapy applications.
In this study we have constructed fusion genes encoding VP22-tk chimeric polypeptides. These proteins were found to retain the intercellular trafficking properties of VP22 and retain the tk enzyme activity. The VP22-tk chimeric proteins spread between cells in sufficient quantities to induce cell death in response to GCV treatment not only in the primary synthesising cells but also in surrounding recipient cells, thus causing a bystander effect 13 in cells devoid of gap junctions. This effect was observed upon GCV treatment of transfected tissue culture cells and in vivo in GCV treatment of mice injected with tumour cells transduced with VP22-tk fusion genes. These results indicate that expression of VP22-tk fusions may prove of benefit in suicide gene therapy approaches to cancer and other diseases.
Results

Expression of the tk fusion proteins
To investigate the ability of VP22 to transport the HSV-1 tk protein from a primary expressing cell to recipient cells, we constructed expression vectors for full-length, in frame, VP22-tk and tk-VP22 fusion proteins driven by the cytomegalovirus immediate-early enhancer/promoter region ( Figure 1a ). In addition we made a tk-tk-VP22 vector which expresses two copies of tk attached to VP22 (Figure 1a) . The chimeric proteins additionally contain an epitope tag at their C-terminus, the detection of which ensures full length synthesis. After transfection into COS-1 cells, the VP22-tk and tk-VP22 vectors generated predominantly full length fusion protein of approximately 90 kDa, which were detected by Western blot analysis (Figure 1d) antibodies. The tk-tk-VP22 expression vector generated a full length protein of approximately 130 kDa, together with some additional truncated products. With the exception of a minor breakdown product of the tk-tk-VP22 fusion, the anti-C-terminal epitope antibody detected almost exclusively the full length proteins (Figure 1c ).
Intercellular transport of the tk fusion proteins
To determine whether the N-and C-terminal tk-VP22 and VP22-tk fusion proteins and indeed the tk-tk-VP22 fusion protein were able to spread from a primary expressing cell into neighbouring cells, COS-1 cell monolayers were transfected with w/t VP22 or the fusion protein constructs, and examined by indirect immunofluorescence. As reported previously, 10 VP22 was present in virtually all the cells in the monolayer, in two main patterns. The lower frequency, more intensely staining cells where VP22 is largely in the cytoplasm ( Figure 2B arrows). Both VP22-tk and tk-VP22 exhibited similar patterns of detection with each of the three antibodies but only data for the anti-epitope antibody is shown in Figure 2 , as this antibody exclusively detects full length fusion proteins. In control experiments, the anti-epitope antibody exhibited very faint cytoplasmic background reaction with mock-transfected cells (Figure 2A ). Monolayers transfected with the parental tk vector showed individual tk-positive cells, in low numbers and as expected no spread of tk into the surrounding cells was observed ( Figure 2 , compare panel C with D/E).
However, for both VP22-tk and tk-VP22, the fusion proteins were present in the majority of cells in the monolayer. As for w/t VP22, intensely staining cells where the fusion protein was largely in the cytoplasm could be readily seen ( Figure 2D and E, long arrows) surrounded by numerous recipient cells where the fusion proteins were located largely in the nucleus ( Figure 2D and E, short arrows). Transport was also observed for the tk-tk-VP22 fusion protein ( Figure 2F ). Over the course of this work, the relative efficiency of transport of the two single copy tk fusions was at least equal to that of w/t VP22, however the tk-tk-VP22 fusion was less efficient, presumably a reflection of its large size.
Thymidine kinase activity
To test whether the tk fusion proteins retained functional activity, we performed thymidine kinase assays both in vitro and in vivo. For the in vitro assays, tk-ve HeLa cells were transfected with each of the constructs, soluble extracts made and conversion of 3 H-thymidine to the phosphorylated form measured by DE81 paper chromatography ( Figure 3a ). For the in vivo assays, tk-ve HeLa cells were transfected with each of the constructs, pulselabelled with 3 H-thymidine and incorporation into TCAprecipitable material then measured (Figure 3b ).
In the in vitro assays, extracts of mock-transfected cells demonstrated very low levels of activity which represented the background for the assay. No significant difference was observed for the VP22 transfected cells. Extracts from cells transfected with either w/t tk, VP22-tk or tk-VP22 demonstrated approximately a 20-fold increase in tk activity above background levels. Slightly weaker but significant increase in tk activity (10-fold) was also observed with the tk-tk-VP22 fusion (Figure 3a) .
Similarly in the in vivo pulse-labelling assay, mock-and VP22-transfected cells incorporated detectable, but very low levels of 3 H-thymidine. Cells expressing either w/t tk or the two fusion proteins generated high levels of incorporation, demonstrating a 10-fold increase above the VP22 control. The tk-tk-VP22 fusion again demonstrated a lower although significant level of activity with a fivefold increase in tk activity above background (Figure 3b ). Thus the results indicate that the VP22-tk fusion proteins retain tk activity in the phosphorylation and incorporation of 3 H-thymidine into DNA in vivo.
GCV induced cytotoxicity in fusion protein-positive cells
To determine whether the tk fusion proteins were also functional in vivo in the activation of the non-toxic prodrug ganciclovir (GCV), to generate a cytotoxic response, COS-1 cell monolayers transfected with each of the constructs were treated with 40 m GCV and harvested 3, 5 ( Figure 4a ) or 8 days after GCV treatment. Cells were stained with trypan blue and assessed for integrity of the monolayer. It can be seen from Figure 4a that both mock-(A) and VP22-(B) transfected monolayers remained intact with no significant effect of the GCV treatment. However GCV promoted pronounced cytotoxicity in monolayers expressing either w/t tk (C),VP22-tk (D) or tk-VP22 (E). By day 5 after GCV treatment only approximately 10% of the monolayer remained, and by day 8 the monolayer was entirely lost. The results indicate that the fusion proteins promoted GCV phosphorylation and subsequent cytotoxicity. However extensive death was also observed with the w/t tk-transfected monolayers suggesting that in these cells a significant proportion of the cytotoxicity observed was the result of a bystander effect.
GCV-induced cytotoxicity in recipient cells in the absence of gap junctions
We next examined GCV induced cytotoxicity in cells which did not exhibit a conventional bystander effect. Neuro 2A cells have poor gap junction cell-cell communications and therefore do not support the GCV bystander effect. 11 COS-1 cells transfected with each of the VP22-tk constructs were co-plated on to untransfected Neuro 2A cells, at a ratio of 1:30 COS/Neuro 2A, and incubated for 24 h, which allowed spread of the fusion proteins from the producer cells into recipient Neuro 2A cells (data not shown). In parallel, the mixed monolayers were then treated with 100 m GCV, harvested at different times after treatment and assayed for cytotoxicity. To visualise the results, a fluorescent-based assay for cell death was used where live cells are labelled green while dead or dying cells are labelled red (see Materials and methods). The results in Figure 4b , 18 h after GCV addition, demonstrate that mock (A), w/t tk (B) and w/t VP22 (C) transfected co-plated monolayers showed only a low percentage of dead cells which were randomly distributed across the monolayer. However for both the VP22-tk fusion proteins, the monolayers exhibited large numbers of dead cells. Furthermore, while single dead cells were observed, uniquely in the monolayers transfected with the VP22-tk fusions we observed cell death in large foci (D and E). These results indicate that the VP22-tk fusions transported from the producer to recipient cells promoted GCV cytotoxicity in both cell types (D and E).
VP22-tk fusions promote GCV-induced tumour regression in vivo
To study whether the results we had obtained in culture could also be observed in vivo we first established Neuro 2A cell lines expressing either the parental tk or the VP22 fusion variants. Retroviral constructs were made (Figure 5a ) expressing either tk, VP22 or VP22-tk fusion genes, together with the selectable neomycin resistance marker and used to establish G418-resistant cell lines expressing each of the proteins. The parental retroviral vector (LN) with no additional insert was used to select G418-resistant Neuro 2A cells as a control. Western blotting of extracts from the selected transduced cells with either anti-tk or anti-VP22 antibody demonstrated the appropriate expression of tk, VP22 or VP22-tk (Figure 5b) . Comparison of detection of tk or VP22-tk with the anti-tk antibody indicated that these proteins were expressed at similar levels in each of the cell types. To rule out the effect of GCV treatment per se on tumour formation, the LN-transduced cells were injected (10 6 ) into four separate locations on the backs of control mice given either saline or GCV. Twenty-five days after cell injection, no significant difference was found between the weight of tumours appearing in the saline control (median mass 1268 mg, range 1008 mg) and GCVtreated mice (median mass 1211 mg, range 1334 mg).
Figure 4 Ganciclovir killing of transfected monolayers. (a) COS-1 cells were transfected as a control with pUC19 (A) or expression vectors for VP22 (B), w/t tk (C), VP22-tk (D) or tk-VP22 (E). Monolayers were treated 24 h after transfection with 100 m GCV and examined for a cytopathic effect 5 days after GCV addition, by phase microscopy. Bar represents 10 m. (b) VP22-tk fusions function in both primary expressing and recipient cells. COS-1 cells transfected with pUC19 (A), VP22 (B), w/t-tk (C), VP22-tk (D) or tk-VP22 (E) expression vectors were co-plated
All animals (n = 19) had small palpable tumours before initiation of the GCV treatment. All animals receiving saline only, developed large tumours at each injection site at the end of the experiments, regardless of the proportion of LN-transduced or LNC-tk, LNC-VP22, or LNC-VP22-tk transduced cells in the injected mixture ( Figure 6, top panel) . Cells containing only VP22 (Figure 6 ,̆) behaved similarly to cells transduced with the LN vector control with no significant difference in either the saline-treated controls or the GCV-treated test animals. Tumours containing 100% LNC-tk (Figure 6, २) or LNC-VP22-tk ( Figure 6 , b) transduced cells were essentially eradicated following GCV treatment ( Figure 6 , bottom panel, 100). This result confirms the retention of tk activity of the VP22-tk fusion protein observed above in culture and in vitro.
All animals receiving the 50:50 mixture of control LNtransduced and LNC-VP22-tk-transduced cells showed a significant tumour weight reduction at the site of inoculation following GCV administration. In this group of animals (n = 5) we observed a reduction in median weight from the control of 1262 mg for 100% LN-transduced cells ( Together with the results of GCV-induced cytotoxicity in tissue culture, these data indicate that, by virtue of its transport properties, VP22 was able to promote a different type of bystander effect, where even in gap junction negative cells, VP22-tk chimeric proteins were able to promote killing of neighbouring tk-negative tumour cells.
Discussion
Previous studies have demonstrated that tk expression and GCV treatment can provide a potent treatment for several tumour types, eg hepatocellular carcinoma 12 and melanomas, 13 particularly those tumours which cannot be completely eradicated by surgery or chemotherapy, eg tumours of the CNS 14 and peritoneal carcinomatosis. 15 However, as with all gene therapy approaches, there remains the problem of delivery of the suicide gene to a high enough percentage of cells to elicit a therapeutic response. While inefficient delivery can be partially counteracted by the bystander effect attributed to tk/GCV treatment, this effect is limited in many tumour types, eg medullablastoma 14 and neuroblastoma 11 cells which have poor cell-cell gap junction communications. Together with the low sensitivity of many tumour types to, for example, retroviral infection as a means of gene delivery, efficient gene delivery remains a major stumbling block in gene therapy.
Here we have demonstrated both in vitro and in vivo, that VP22 can be used to deliver functional tk protein from an expressing cell into many neighbouring cells, in the absence of gap junctions, where it functions in the phosphorylation of the nucleoside analogue GCV, promoting cytotoxicity in dividing cells in culture and tumour regression in vivo. Cell death induced by tk can occur via apoptotic-independent 11, 16 or dependent routes 5, 16 and the latter pathway may not require p53. 17, 18 Therefore tk/GCV treatment may also be applicable in therapy of p53-mutated tumours.
One factor in consideration of VP22 for clinical use relates to the fact that it is a viral protein and therefore immunogenicity of VP22 and the corresponding fusion proteins may be observed and could hamper its use. Nothing is currently known about immune responses to VP22. However as immune responses have been shown to play an important role in several forms of experimental suicide gene therapy, [19] [20] [21] it is possible that immunogenicity of VP22 may even prove beneficial in this setting.
While we were unable to demonstrate a VP22-mediated bystander effect using admixes with 25% of the transduced cells, we have noted in transient transfections that expression levels of the VP22-tk fusion proteins from the retrovirus LTR is low compared with expression from the CMV enhancer/promoter. We anticipate that the levels of expression of VP22-tk fusion proteins may be an obvious limiting factor in the amount of spread and the resulting bystander effect. Further work is now in progress to establish similar Neuro 2A lines with the test fusions under the control of the CMV promoter and to examine GCV tumour regression with these lines in vivo.
In conclusion, these results together with our recent demonstration of delivery of functional p53, 22 indicate that VP22 may serve as a versatile protein delivery mechanism whereby candidate proteins can be delivered in a functional form to many more cells than those receiving the transducing vector. While many additional issues need to be addressed and VP22-mediated delivery may itself be improved, such amplification in delivery may help overcome one of the major hurdles in gene therapy. 
Materials and methods
Plasmids
The plasmid pc49epB 22 contains the VP22 open reading frame flanked at its N-and C-terminal ends by unique Bg1II and BamHI sites, respectively. The VP22 coding region reads in frame to the epitope sequence ERKTPRVTGG (ep) which is recognised by the monoclonal antibody CMV-018-48151 (Capricorn Products, Scarborough, ME, USA). The coding region for tk was amplified by PCR and cloned into the unique BglII site for N-terminal fusions (ptk-VP22ep) or the unique BamHI site for C-terminal fusions (pVP22-tkep) such that VP22, tk and the epitope remained in frame for protein expression.
To generate retroviral vectors containing HSV-tk, VP22 and VP22-tk, we used the LN vector, which is derived from Moloney murine leukaemia virus and carries the bacterial neomycin phosphotransferase gene (neo R ) in the retroviral backbone. 23 To make the LNC parental vector, the IRES (internal ribosomal entry site for the encephalomyocarditis virus) from pCITE (Novagen, Maison, USA) was cloned into the LN vector.
To generate the vector LNC-VP22, a BglII to PstI fragment of pcUL49epB containing the entire VP22 coding region including the C-terminal epitope tag was inserted into the LNC vector. To make LNC-VP22-tk the BamHI tk fragment from pVP22-tkep was inserted into the BamHI site of the LNC-VP22. To generate the LNC-tk, the BamHI tk fragment from pVP22-tkep was cloned first into the shuttle plasmid pSL301 (Stratagene, La Jolla, CA, USA) and then into the LN vector. The producer cell line, BOSC 24 was transfected with each of the plasmids by polyethyleneimine 25 kDa (Aldrich, Milwaukee, WI, USA) as previously described. 25 Supernatants were collected from the BOSC cells and used to transduce the Neuro 2A cells. After two rounds of transduction in the presence of 4 g/ml polybrene at 37°C, 5% CO 2 , Neuro 2A cells were cultured in selection medium containing the G418 neomycin analogue (Life Technologies). After 2 weeks of G418 selection, resistant cells were obtained for subsequent experiments.
Cell lines COS-1 and HeLa cells were grown in DMEM + 10% NBCS (Life Technologies, UK). The tk-ve HeLa cells Bu25 tk-(ECCC, Porton Down, UK) were cultured in EMEM + 2 mm l-glutamine, 1% NEAA and 10% FBS (Life Technologies, UK). The Neuro 2A neuroblastoma cell line, from a spontaneous tumour of a strain A albino mouse (ATCC, Rockville, MD, USA) was grown in Dulbecco's modified Eagle's supplemented with 10% FBS and 2 mm l-glutamine.
Antibodies
Polyclonal anti-VP22 antibody AGV30 10 and the anti-epitope antibody were used as previously described. 22 Polyclonal anti-tk antibodies were used at 1:1000 for Western blot, 1:100 for immunofluorescence (Figure 1 ) or at 1:500 for Western blot ( Figure 5 ).
Transfection
For immunofluorescence, 3 H-thymidine incorporation and ganciclovir cytotoxicity assays, cells were plated at 2 × 10 5 cells per 35-mm well and transfected with 1 g of expression plasmid, made up to 2 g with pUC19 DNA, using the calcium phosphate precipitation technique modified with BES-buffered saline as previously described. 10 For the in vitro tk assay, 50-mm dishes were seeded at 4 × 10 5 cells per dish and transfected with 4 g of expression plasmid.
Western blot analysis
Western blot analyses of total extracts of transfected cells were performed as previously described. 22 For the G418 selected transduced cells ( Figure 5 ) protein content was quantified by MicroBCA protein assay (Pierce, Rockford, IL, USA) and equal amounts separated on a 10% SDS-PAGE gel, transferred to nitrocellulose membranes and probed with the AGV30 or anti-tk antibodies.
Immunofluorescence and microscopy Microscopy procedures were performed as described previously.
H-thymidine incorporation assay
Monolayers of tk-ve HeLa cells (70% confluent) were transfected as described above. Culture medium was replaced 40 h after transfection with media containing 3 H-thymidine at 20 Ci/ml and incubated for a further 2.5 h. The monolayers were washed, harvested and the amount of 3 H-thymidine incorporated into TCA precipitable material measured by binding on to GF/C glass microfibre filters (Whatman, UK) as previously described. 26 In vitro thymidine kinase assay Monolayers of tk-ve HeLa cells (70% confluent) transfected as described above were harvested 40 h after transfection and extracted in 200 l of a buffer containing 400 mm NaCl as described previously.
10 Aliquots (5 l) were incubated in 0.2 m Tris pH 8.2, 5 mm MgCl 2 , 5 mm ATP, 1 Ci 3 H-thymidine, for 10 min at 37°C and the reaction stopped by boiling. Duplicate samples of the mix (20 l) were dried on to DE81 paper discs (Whatman) and counted directly (unwashed control), or washed under vacuum with 3 × 20 ml washes of 1 mm ammonium formate (pH 3.6) and dried for a further 1 h. Bound, phosphorylated, 3 H-thymidine counts were measured in a scintillation counter. 26 Fluorescent viability/cell death assay This assay examines cell viability by measuring calcein-AM uptake and esterification, which results in green fluorescence, and cell death by measuring uptake of ethidium bromide dimers which results in red fluorescence and was performed according to the manufacturer's instructions (Molecular Probes, Leiden, The Netherlands). 
Statistical analysis
The Wilcoxon Mann-Whitney test was used in the statistical analysis of the in vivo bystander effect. The levels are expressed as median ± range. Differences were considered significant when P р 0.05.
